Vaso Corporation (VASO) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Vaso Corporation (VASO) Healthcare & Pipeline Overview

Vaso Corporation provides healthcare IT solutions, medical devices, and professional sales services, primarily focusing on diagnostic imaging and therapeutic systems. With a market capitalization of $52.8M, the company operates through IT, Professional Sales Service, and Equipment segments, serving healthcare providers both domestically and internationally.

What Is the Investment Thesis for VASO?

Vaso Corporation presents a mixed investment profile. The company's gross margin of 60.9% and ROE of 9.6% indicate efficient operations and profitability. Its low beta of 0.49 suggests lower volatility compared to the broader market. A profit margin of 2.9% demonstrates the ability to convert revenue into profit. Growth catalysts include expansion of the IT segment and increased sales of proprietary medical devices. However, the high debt-to-equity ratio of 7.19 and the absence of a dividend may deter some investors. The company's reliance on GEHC for equipment sales also poses a risk. The market capitalization of $52.8M reflects its small size and potential for growth, but also exposes it to risks associated with smaller companies.

Based on FMP financials and quantitative analysis

VASO Key Highlights

Gross margin of 60.9% indicates strong pricing power and efficient cost management.

• Return on Equity (ROE) of 9.6% demonstrates the company's ability to generate profit from shareholders' investments.
• Debt-to-Equity ratio of 7.19 suggests a highly leveraged financial structure, which could pose risks.
• Profit margin of 2.9% shows the percentage of revenue that turns into profit.
• Market capitalization of $52.8M reflects its small size and growth potential.

Who Are VASO's Competitors?

What Are VASO's Key Strengths?

Diverse product and service offerings across IT, sales, and equipment segments.

• Established partnership with GE Healthcare.
• Proprietary medical device technology.
• Recurring revenue from IT service contracts.

What Are VASO's Weaknesses?

Small market capitalization limits access to capital.

• High debt-to-equity ratio increases financial risk.
• Reliance on GE Healthcare for equipment sales.
• Limited brand recognition compared to larger competitors.

What Could Drive VASO Stock Higher?

Expansion of the IT segment with new software solutions for diagnostic imaging.

• Increased sales of proprietary medical devices, such as Holter monitors and wireless vital-sign monitoring systems.
• Strategic partnerships to expand product offerings and market reach.
• Geographic expansion into new markets.

What Are the Key Risks for VASO?

Financial-distress signal — its Altman Z-Score of 1.24 sits in the distress zone (elevated bankruptcy risk).

• Competition from larger, more established players in the healthcare IT and medical device markets.
• Technological obsolescence of medical devices.
• Regulatory changes impacting healthcare IT and medical devices.
• High debt-to-equity ratio increases financial risk.
• Reliance on GE Healthcare for equipment sales.

What Are the Growth Opportunities for VASO?

• Expansion of IT Segment: Vaso Corporation can expand its IT segment by offering advanced healthcare software solutions and managed network services. The healthcare IT market is projected to reach $390 billion by 2027, driven by the increasing adoption of electronic health records and the need for data security. By investing in innovative IT solutions, Vaso Corporation can attract new clients and increase its market share. Timeline: Ongoing.
• Increased Sales of Proprietary Medical Devices: Vaso Corporation can increase sales of its proprietary medical devices, such as Biox series Holter monitors and MobiCare wireless vital-sign monitoring systems. The market for remote patient monitoring devices is expected to reach $1.9 billion by 2028, driven by the growing prevalence of chronic diseases and the increasing demand for home healthcare. By focusing on product innovation and marketing, Vaso Corporation can capture a larger share of this market. Timeline: Ongoing.
• Strategic Partnerships: Vaso Corporation can form strategic partnerships with other healthcare companies to expand its product offerings and reach new markets. By partnering with companies that offer complementary products and services, Vaso Corporation can create a more comprehensive solution for its clients. Timeline: Ongoing.
• Geographic Expansion: Vaso Corporation can expand its geographic presence by targeting new markets in the United States and internationally. The global healthcare market is growing rapidly, driven by the increasing demand for healthcare services in developing countries. By establishing a presence in new markets, Vaso Corporation can diversify its revenue streams and reduce its reliance on the U.S. market. Timeline: Ongoing.
• Enhanced External Counterpulsation (EECP) Therapy Systems: With the increasing prevalence of ischemic heart disease, Vaso Corporation can focus on expanding the reach of its EECP therapy systems. As a non-invasive outpatient treatment, EECP presents a compelling alternative to more invasive procedures, aligning with the growing preference for less intrusive medical interventions. By increasing awareness and adoption of EECP, Vaso Corporation can tap into a significant market opportunity. Timeline: Ongoing.

What Are VASO's Competitive Advantages?

• Established relationships with GE Healthcare.
• Proprietary medical device technology.
• Recurring revenue from IT service contracts.
• Specialized expertise in healthcare IT and medical devices.

What Does VASO Do?

Vaso Corporation, originally incorporated as Vasomedical, Inc. in 1987 and renamed in 2016, operates within the healthcare equipment and information technology sectors. The company is structured into three primary segments: IT, Professional Sales Service, and Equipment. The IT segment delivers managed healthcare software solutions, encompassing diagnostic imaging applications, network infrastructure management, network transport, and security services. This segment is crucial for healthcare providers seeking to optimize their IT infrastructure and ensure data security. The Professional Sales Service segment focuses on facilitating the sale of healthcare capital equipment from General Electric Healthcare (GEHC) to health providers, particularly targeting the middle market. This includes GEHC diagnostic imaging equipment, ultrasound systems, service agreements, training, and financial services, providing a comprehensive suite of solutions for healthcare facilities looking to upgrade or expand their equipment base. The Equipment segment is dedicated to the design, manufacture, and service of proprietary medical devices and software. Products include the Biox series Holter monitors and ambulatory blood pressure recorders, ARCS series analysis software for ECG and blood pressure signals, MobiCare multi-parameter wireless vital-sign monitoring systems, and Enhanced External Counterpulsation (EECP) therapy systems for treating ischemic heart disease. These devices cater to the growing need for non-invasive and outpatient treatment options. Based in Plainview, New York, Vaso Corporation serves a diverse range of healthcare providers in the United States and internationally.

What Products and Services Does VASO Offer?

• Provides healthcare IT solutions, including diagnostic imaging applications.
• Offers managed network infrastructure, transport, and security services.
• Sells healthcare capital equipment for General Electric Healthcare (GEHC).
• Offers GEHC diagnostic imaging equipment and ultrasound systems.
• Manufactures and services proprietary medical devices and software.
• Produces Biox series Holter monitors and ambulatory blood pressure recorders.
• Develops ARCS series analysis software for ECG and blood pressure signals.
• Offers MobiCare multi-parameter wireless vital-sign monitoring systems.

How Does VASO Make Money?

• Generates revenue through the sale of healthcare IT solutions and services.
• Earns commissions from the sale of GEHC healthcare capital equipment.
• Derives revenue from the sale and service of proprietary medical devices.
• Offers software subscriptions and algorithm services for ECG and blood pressure analysis.

What Industry Does VASO Operate In?

Vaso Corporation operates in the health information services industry, which is experiencing growth due to the increasing adoption of healthcare IT solutions and the rising demand for remote patient monitoring. The industry is characterized by technological advancements, regulatory changes, and competitive pressures. Vaso Corporation's focus on healthcare IT, medical devices, and professional sales services positions it to capitalize on these trends. However, it faces competition from larger, more established players in the market.

Who Are VASO's Key Customers?

• Hospitals and healthcare systems
• Diagnostic imaging centers
• Physician practices
• Outpatient clinics

Vaso Corporation (VASO) Valuation Context

Valued at $52.8M, VASO is classified as a micro-cap stock. Relative to its peer group, VASO's quantitative score of 49/100 is roughly in line with the peer average of 55/100.

VASO Revenue & Earnings Trend

In Q2 2026, VASO generated $11.2M in top-line revenue, marking a sequential decrease of 42.2%. The company recorded net income of $840K, with diluted EPS of $0.00. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, VASO averaged $0.00 in diluted EPS.

Company Profile

Vaso Corporation operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Plainview, US. The company is led by CEO Jun Ma. VASO has traded publicly since 1995.

Return on equity for Vaso Corporation stands at 6.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.1%, showing how much profit it generates from its asset base. VASO trades at a trailing price-to-earnings ratio of 26.04, above the Healthcare sector average of ~23x. Its free cash flow yield is -8.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.67 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.8%, the inverse of the P/E and a quick read on earnings relative to price.

Vaso Corporation's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.24 places it in the distress zone, a signal of elevated financial risk.

VASO Financials

VASO Latest News

No recent news available for VASO.

VASO Analyst Consensus

VASO MoonshotScore

Vaso Corporation Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources